Subscribe (Free) to our channel for expert advice, support, and real stories from the world's leading nonprofit for prostate cancer survivors. Stay informed and empowered—hit the subscribe link here:
[ Ссылка ]
Discover how Lutetium 177 offers new hope for men with metastatic castration-resistant prostate cancer (MCRPC). This cutting-edge treatment uses radioligand therapy (RLT) to target cancer cells with precision, slowing tumor growth when other treatments have failed. In this video, we explain how Lutetium 177 works by binding to PSMA proteins on cancer cells, delivering targeted radiation while minimizing damage to healthy tissue. Learn about the treatment process, who qualifies for this therapy, and what to expect, including potential side effects, and the critical role of PSMA PET scans in determining eligibility.
